59 VX-950, a novel HCV protease inhibitor, retains potency against BILN-2061 resitant replicon cells: Computational analysis indicates that resistance develops via different mechanisms
Keyword(s):
2018 ◽
Vol 84
(5)
◽
pp. 961-971
◽
Keyword(s):
2012 ◽
Vol 52
(10)
◽
pp. 1574-1583
◽
2010 ◽
Vol 5
(3)
◽
pp. 158-173
◽
Keyword(s):
2013 ◽
Vol 68
(6)
◽
pp. 1415-1422
◽
2007 ◽
Vol 73
(1)
◽
pp. 78-83
◽